U.S. Markets closed

Gilead Sciences, Inc. (GILD)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
83.27+0.65 (+0.79%)
At close: 4:00PM EDT
People also watch
CELGBIIBAMGNBMYREGN
  • T
    Tim
    Tim
    I have a good feeling we'll see a steady march to low 90's in the run up to earnings. It would appear this action is somewhat predictable given the price movement the last 2-3 years. I have been long for 6 plus years and am very positive post-KITE acquisition. I'm not even sure, absent some huge aberration, the actual earning results even matter, they certainly didn't on the way down. Go GILD!!
  • B
    B
    B
    NASH results end of this month?
  • s
    stockdog87
    stockdog87
    Went to see the gypsy, she told me GILD will break threw $83.50 today or tomorrow. Just thought I'd share my recent technical analysis.
  • C
    Crash
    Crash
    $79 next week. That was a nice run to mid $80's Hope all that were patient did well and took some profit. Also, if you originally bough in the $80's, it was a good time to get whole and wait for the next pull back. If you did not, oh well.... I think GILD will hit $90's before year end anyway. My opinion
  • T
    Tim
    Tim
    some interesting buying at fairly large volume going on. I wonder if GILD is getting ready to pull the trigger again and it's leaked. odd, but nice direction
  • b
    bill
    bill
    discount alert gild brass. buy icpt now and corner nash mkt too. they will also corner hbv and car t mkt. locked and loaded
  • F
    Frank B
    Frank B
    abbvie has 7 % of new hep C prescriptions, big deal thats
    less than one prescription for every ten that is written by Gilead.
  • P
    Paul
    Paul
    43.
    45.5
    49.98
    53.53
    61.07
    69.68
    73.03
    76.89
    81.01

    O.

    .
  • H
    HiTechInvesting
    HiTechInvesting
    $GILD and HTBX on cancer
  • m
    mr.phil2u
    mr.phil2u
    Personal Information hack.
    Everyone should be aware of equifax personal information theft. It's very easy to freeze your credit. It took me about 20 minutes to freeze credit with all three reporting agencies. Now no one can open up a account in my name.
  • C
    Crash
    Crash
    dead zone. that run from $60's to $mid $80's has petered out. although nice while it lasted, appears not many willing to enter at this price. hoping for another run in the $70's next week. my opinion
  • T
    Tim
    Tim
    I'm not too concerned about the pullback. It's had a nice run and it's good to have consolidation. GILD did what it had to do, and should have done two years ago, buy a stream of revenue. No worries here, talk to me in a year if we're still moving sideways or down.
  • C
    Crash
    Crash
    Hopefully those that bought at $80 before to advantage of opportunity to get whole. When it crossed $85 that was a dream come true. If you got greedy and did not close out position, let this be a lesson to you. Keep in mind GILD was as low as $63's at one point and there were a lot of buyers down there. Now they are off loading positions it appears. This market can give it and take it away fast. My opinion
  • b
    bill
    bill
    wow this MB quiet today. so who are we gona buy next 😀
  • P
    Paul
    Paul
    Re: O.YdidI(s)@OPEN.

    Re: IdidNot.

    o.

    .
  • T
    Tad
    Tad
    $ARWR conversation

    from sa advisory

    On Sept 14, 2017 key personal will discuss the advancements of ARWR and also the joint venture with AMGN. To recap~ ARWR will provide an overview of the Company's new platform technology and its pipeline of RNAi- based therapeutics. This discussion will include:

    1. The targeted RNAi Molecule (TRiM) Platform, which includes targeted to the liver, tumors, and another tissue to be disclosed at the event.

    2.ARO-AAT for liver disease associated with alpha-1 antitrypsin deficiency,

    3. ARO-HBV for chronic hepatitis B infection

    4. ARO-APOC3 for cardiovascular diseases

    5. Updates on ARWR's clinical development timelines

    Note: A live and achived webcast of the event,with slides~ http://ir.arrowheadpharma.com/events.cfm.

    Please recall back on Sept 29th 2016 ARWR/AMGN created a Cardiovascular Collaboration for 2 RNAi therapeutics. The Total deal value of up to $673.5 million. ARWR received $56 million up front. The herd will have "big ears" concerning the outcome of this collaboration. Via the grapevine there has been chatter that both companies will be formally introducing a FDA filing on potential drug testing . If the mere mention of this advanced FDA process they herd will have a bullish stampede on the upside and shorts will hang themselves if they can even afford the rope!

    Biotechs are the toughest investment speculation to be found anywhere. If cash burn-rate was not hard enough to swallow you then need to deal with "gods" of the FDA! Fortunes can be had as well as potentially vying for an abandoned shopping cart.

    Like a "hurricane" the FDA can clip millions or billions off the value of a company's market-cap with a 4 letter word-"DENY"!

    Last November 2016 the FDA "clipped" ARWR when the Arrow's lab somehow OD'd a few chimps and regardless how successful the human trial had gone- the FDA punished ARWR causing the stock to free fall from $6.00 to $1.20! Faster than a hand of Blackjack !

    At the same time AMGN decided to throw ARWR a small bone with the possibility of a large Dinosaur bone ($622,000,000.00) if results from a new platform could create a Cardio cancer drug. At present AMGN is funding the company for their research with more money to be released if results are juicy enough!

    We still believe that ARWR is still deep into their RNAi based therapeutic platform. In a nutshell RNAi is the mechanism that offers a pathway of gene silencing to target and shut down specific genes that cause disease.

    Note: go to www.amgenscience.com and click,"the shape of drugs and go down and click RNAi. There is more than meet the eye between AMGN/ARWR.

    The large sum of money mentioned above with AMGN deals with a program to utilize ARWR's proprietary subcutanous RNAi delivery platform for therapies for cardiovascular disease. Part of the agreement grants AMGN worldwide, exclusive license to ARWR's novel, RNAi-ARC-LPA program. These RNAi molecules are designed to reduce elevated lipoprotein(a), which is a genetically validated, independent risk factor for atherosclerotic cardiovascular disease.

    In our opinion, if AMGN continues to like the results i see very little reason why AMGN would continue to fund the company, but instead just buy them.

    ARWR is extremely rich with patents, technology and capable science so AMGN gets many valuable extras. Lately, the Biotech segment has been active in the M&A area -KITE was just swallowed by Gilead for $12 billion! Many of these Biotech's are swimming with hordes of cash and i believe Gilead has just woken up the major players to start grabbing deals before the other guy snags them!

    AMGN is a "GOD" of the Biotech sector. At present they have $39,000,000,000 in cash and their stock is $180.00/sh and there are around 730 million shares outstanding.

    The fantasy: Amgen buys ARWR for $20/sh because the results announced on Sept 14th and beyond indicate enormous potential. If AMGN paid cash that would only be $1.5 Billion. Personally, if i was AMGN i would use their stock and it would only cost around 8.3 million shares of AMGN stock. Like a drop of water in a puddle.

    Food for thought: Silence Therapeutics owns over 9% of ARWR free trading shares.

    phone: +44 (0)20 3457 6900

    website: www.silence-therapeutics.com

    The company is heavy into RNAi research and development.

    We have been involved in ARWR for a number of years and have felt the euphoria and level 9 of HELL!

    ARWR has been involved with Gilead (GILD-$85) ,Novartis (NVS-$86) and Amgen (AMGN-$180).

    It is only a matter of time before one of these giants takes out ARWR because of their results, platforms, science, patents and most importantly results. We rate ARWR with a strong buy rating. It maybe like playing dice, but in our case even if you throw a snake eyes we still have the potential to throw 7 at a later date.

    On Sept 14, 2017 the cards will be on the table. There will be 3 options: 1.the street already assumed the steady potential with AMGN and the stalls and the short lick their chops!

    2. Results are less than anticipated and the stocks drops to low $2 range even though AMGN continues the research and still will fund.

    3. We hit certain milestones and results are very favorable and the stock rockets!

    Regardless, we believe a good price ($3.39) to build a position in this biotech opportunity with amazing upside potential .

    $ARWR $GILD $AMGN $NVS

  • F
    Frank B
    Frank B
    Ben from Barron's still dumping on gilead , nothing makes him happy or the people he ask's for their opinions.
  • M
    Michael
    Michael
    FF
    Yesterday you alleged on the KITE message board that the KITE shareholder class action law suit was a nuisance case. It was filed by three different KITE plaintiffs. You alleged that Mr. Robert Berg filed a prior nuisance law suit. Prove and document your allegation that Mr. Robert Berg filed a prior nuisance plaintiff action law suit.
    While your'e at it, also prove and document that the other two KITE plaintiffs ever filed prior nuisance law suits too.
  • J
    Jon
    Jon
    The Kite deal is history. Disenchanted shareholders can complain till the cows come home. It's like the 2016 elections, Trump won and Hilary lost...get over it!
  • V
    Victor
    Victor
    No interest in GILD. Volume is down to the previous low's. Even with the rumors of potential higher dividend investor don't see the catalyst . Today Pop was a one day event since it got upgrade because of low PE. The anticipated sales decline of 30% its reflected on the PE. It will start the trend down tomorrow expect to be below $80 by Friday.